Outro raises $7M to scale supervised antidepressant tapering
CEO Brandon Goode says a gap he saw in psychedelic care led him to build an off-ramp for patients struggling to stop long-term medication.
By RuntimeWire Staff · Published

CEO Brandon Goode says a gap he saw in psychedelic care led him to build an off-ramp for patients struggling to stop long-term medication.